Neuronetics Stock Forum

$Neuronetics (STIM.US)$
NeuroStar Unveils Two Significant Publications on TMS Therapy for Depression
Wednesday, 29th January at 8:31 am
MALVERN, Pa., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced two peer-reviewed publications in the inaugural edition of the Transcranial Magnetic Stimulation j...

$Neuronetics (STIM.US)$
CCORF analyst William Plovanic maintains $Neuronetics (STIM.US)$ with a buy rating, and maintains the target price at $3.
According to TipRanks data, the analyst has a success rate of 45.4% and a total average return of 1.4% over the past year.

$Neuronetics (STIM.US)$ this like going to fly again

$Neuronetics (STIM.US)$
Neuronetics and Greenbrook TMS Announce Closing of Transaction
Tuesday, 10th December at 10:00 am
MALVERN, Pa. and TORONTO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) ("Neuronetics") and Greenbrook TMS Inc. (OTC: GBNHF) ("Greenbrook", and together with Neuronetics, the "Combined Company") today announced that they have successfully completed the previously announced transaction whereby Neuronetics acquired all of the issued and outstanding commo...

$Neuronetics (STIM.US)$
NeuroStar® Oral Presentation at AACAP 2024 Highlights Largest Study Evaluating TMS Efficacy in Adolescents with Depression
Neuronetics, Inc. (NASDAQ: STIM) announced its participation at the American Academy of Child and Adolescent Psychiatry (AACAP) conference in Seattle, WA, from October 14th-19th. The company will present data on the NeuroStar TMS System in an oral presentation at the 'Research Pipeline: New Findings on Therapeutics' session. This presentation will ...

$Neuronetics (STIM.US)$
Health Care Service Corporation Adds First-Line TMS Coverage for AdolescentsNeuronetics, Inc. (NASDAQ: STIM) announced that Health Care Service (HCSC) has expanded access to TMS (transcranial magnetic stimulation) for adolescents 15 and older with major depressive disorder (MDD). This policy update aligns with the recent FDA clearance of NeuroStar TMS Therapy as a first-line add-on treatment for this age group. HCSC, the largest customer-owned health insurer in the U.S...

$Neuronetics (STIM.US)$ Expanded Health Policies Enhance TMS Therapy Access for Adolescents and Adults
3 MINUTES AGO, 8:31 AM EDT
VIA GLOBENEWSWIRE
MALVERN, Pa., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that additional payors have updated their TMS (transcranial magnetic stimulation) cove...

$Neuronetics (STIM.US)$
NeuroStar® Releases Software Upgrades to Elevate Patient Care
Neuronetics (NASDAQ: STIM) has announced significant upgrades to its NeuroStar Advanced Therapy and TrakStar® patient data management software. The enhancements focus on improving patient communication, streamlining clinical data capture, and strengthening cybersecurity. Key upgrades include:
1. Enhanced Patient Communication: New CRM capabilities for automated SMS and email communication, secure insurance ...